OGT to Share Strategies for Reliable NGS Panel Assays
Oxford Gene Technology (OGT), provider of innovative genetics research and biomarker solutions to advance molecular medicine, will share its expertise in NGS assay design by hosting a live webinar entitled ‘Enhanced bait design strategies that deliver more reliable NGS panel assays’ on 3 October 2013, at 3:00pm (BST).
Guest speaker, Dr Chris Mattocks, Senior Clinical Research Scientist at the National Genetics Reference Laboratory (Wessex), Salisbury UK, will discuss the advantages of hybridisation enrichment and the importance of optimal bait design to ensure increased uniformity for all target regions.
As the use of NGS moves closer to the clinic, it is of paramount importance that relevant mutations can be detected and called with complete certainty. Only reliable and reproducible methods will inspire enough confidence to allow the transition of NGS assays from useful research tools to clinically dependable tests.
As such, it is becoming increasingly apparent that some NGS enrichment methods do not reliably detect known mutants due to issues with PCR artefacts, excessive off-target enrichment, target region bias, non-uniformity of coverage or even wholesale target region drop-out. This highlights the need for methods with increased uniformity of coverage (when each locus is read at sufficient depth without resorting to increasing the number of reads) and minimal variation between loci, to provide confidence that all loci are covered at dependable levels.
As well as discussing bait design, the webinar will also cover the impact of coverage, non-conformity on sequencing efficiency and cost, and how coverage affects confidence levels in the results.
OGT’s significant expertise in NGS is demonstrated by Genefficiency Custom Targeted Sequencing Services, which combine expert bait design with a unique and fully interactive variant analysis report that delivers rapid access to reliable, meaningful results.
To register for the webinar, please visit the sign-up page.
Related News
-
News Understanding the Benefits and Advances of Cleanroom Technology
In an industry where precision and sterility are crucial concerns, cleanrooms play a vital role in maintaining the integrity of pharmaceutical products like drugs, vaccines, and other medical products. So, what is a cleanroom?
-
News AbbVie secures GBP£1.2 billion deal for Gilgamesh’s psychedelic programme
AbbVie has penned a significant agreement to acquire the bretisilocin programme from Gilgamesh Pharmaceuticals for up to £1.2 billion, marking a bold step in the pharmaceutical giant's quest to develop treatments for psychiatric disorders. -
News Gates Foundation commits US$2.5 billion to women’s health research
The Bill & Melinda Gates Foundation has announced a substantial US$2.5 billion commitment to accelerate research and development focused exclusively on women's health through 2030.
-
News Mid-year review: notable FDA drug approvals of 2025
As we fly past the halfway point of 2025, the pharmaceutical landscape reliably continues to evolve with innovative therapies addressing critical medical needs. The FDA has already approved 17 groundbreaking medications this year, each representin... -
News US FDA announces new priority vouchers for accelerated review times
The US FDA announced a new priority program for drug developers – the Commissioner’s National Priority Voucher (CNPV) program aims to enhance the health interests of the US by allowing drug developers to redeem a voucher, shortening th... -
News Google-backed start-up raises US$600 million to support AI drug discovery and design
London-based Isomorphic Labs, an AI-driven drug design and development start-up backed by Google’s AI research lab DeepMind, has raised US$600 million in its first external funding round by Thrive Capital. The funding will provide further power t... -
News AstraZeneca to invest US$2.5 billion in Beijing R&D centre
Amid investigations of former AstraZeneca China head Leon Wang in 2024, AstraZeneca have outlined plans to establish its sixth global strategic R&D centre in China. Their aim is to further advance life sciences in China with major research and manufact... -
News Experimental drug for managing aortic valve stenosis shows promise
The new small molecule drug ataciguat is garnering attention for its potential to manage aortic valve stenosis, which may prevent the need for surgery and significantly improve patient experience.